Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis (Q34677487)

3 August 2017

0 references

Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

Jose R Maneiro

2

0 references

Loreto Carmona

object named as

Loreto Carmona

series ordinal

3

0 references

author name string

Eva Salgado

series ordinal

1

1 reference

3 August 2017

Juan J Gomez-Reino

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

18 April 2013

1 reference

Annals of the Rheumatic Diseases

3 August 2017

published in

1 reference

3 August 2017

volume

73

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

871-882

1 reference

The protein kinase complement of the human genome

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

The structural basis for control of eukaryotic protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: does variable inhibition of interleukin-6 production limit effectiveness in vivo?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Kinase inhibitors: a new class of antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

The riddle of the mast cell: kit(CD117)-ligand as the missing link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Therapeutic targeting of c-KIT in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

A multitude of kinases--which are the best targets in treating rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Inhibition of p38: has the fat lady sung?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

"Go upstream, young man": lessons learned from the p38 saga

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203116

10.1136/ANNRHEUMDIS-2012-203116

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference